<h3>认识塞缪尔 – 您的个人投资先知</h3>
<ul>
<li>与 TipRanks 的可信、数据驱动的投资智能开始对话</li>
<li>向塞缪尔询问股票、您的投资组合或市场，并在几秒钟内获得即时、个性化的见解</li>
</ul>
<p>Treace Medical Concepts (TMCI) 发布了最新动态。</p>
<p>在 2026 年 5 月 19 日举行的年度股东大会上，Treace Medical Concepts, Inc. 的股东选举了二级董事兰斯·A·贝里、伊丽莎白·S·汉娜和简·E·基尔南，任期三年，至 2029 年年度会议结束。投票结果重申了现有董事会结构，并表明对公司当前战略方向的持续支持。</p>
<p>股东还以咨询和非约束性的方式批准了公司指定高管的薪酬计划，表明投资者对管理层薪酬做法的广泛支持。此外，股东确认了格兰特·桑顿会计师事务所作为截至 2026 年 12 月 31 日的财政年度独立注册公共会计师的任命，强化了公司财务监督和审计框架的连续性。</p>
<p>对 (TMCI) 股票的最新分析师评级为持有，目标价为 2.00 美元。要查看 Treace Medical Concepts 股票的完整分析师预测列表，请参见 TMCI 股票预测页面。</p>
<p><strong>Spark 对 TMCI 股票的看法</strong></p>
<p>根据 Spark，TipRanks 的 AI 分析师，TMCI 的评级为中性。</p>
<p>该评分主要受到财务表现不佳的制约——持续亏损和负自由现金流——尽管毛利率强劲且现金消耗有所改善。技术面短期支持，但似乎被高估，仍低于 200 日均线。由于盈利为负，估值提供的支持有限，而最新指引表明，近期收入压力仍在持续，同时努力减少现金使用。</p>
<p>要查看 Spark 对 TMCI 股票的完整报告，请点击这里。</p>
<p><strong>关于 Treace Medical Concepts 的更多信息</strong></p>
<p>Treace Medical Concepts, Inc. 是一家医疗设备公司，开发和营销针对足部和踝部疾病的外科解决方案，特别关注拇外翻矫正手术。该公司以骨科外科医生和足病医生为目标，在更广泛的医疗技术行业中定位于专业的骨科和足病外科市场。</p>
<p><strong>平均交易量：</strong> 857,905</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> 1.784 亿美元</p>

TMCI

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>在 Treace Medical 的年度会议上，股东选举了三年任期的董事，批准了高管薪酬，并确认 Grant Thornton 为 2026 年的审计师。董事会的结构得到了强有力的支持，表明对公司战略的信心。分析师对 TMCI 股票的评级为持有，目标价为 2.00 美元，指出尽管毛利率强劲，但财务表现疲弱。该公司专注于足部和踝部疾病的外科解决方案</p>

<h3>Meet Samuel – Your Personal Investing Prophet</h3>
<div class="lb-trans"><h3>认识塞缪尔 – 您的个人投资先知</h3>
</div><ul>
<li>Start a conversation with TipRanks’ trusted, data-backed investment intelligence</li>
<li>Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds</li>
</ul>
<div class="lb-trans"><ul>
<li>与 TipRanks 的可信、数据驱动的投资智能开始对话</li>
<li>向塞缪尔询问股票、您的投资组合或市场，并在几秒钟内获得即时、个性化的见解</li>
</ul>
</div><p>Treace Medical Concepts ( (TMCI) ) has shared an update.</p>
<div class="lb-trans"><p>Treace Medical Concepts (TMCI) 发布了最新动态。</p>
</div><p>At its annual meeting of stockholders held on May 19, 2026, Treace Medical Concepts, Inc. shareholders elected Class II directors Lance A. Berry, Elizabeth S. Hanna and Jane E. Kiernan to three-year terms ending with the 2029 annual meeting. The voting results reaffirmed the existing board structure and suggest continued support for the company’s current strategic direction.</p>
<div class="lb-trans"><p>在 2026 年 5 月 19 日举行的年度股东大会上，Treace Medical Concepts, Inc. 的股东选举了二级董事兰斯·A·贝里、伊丽莎白·S·汉娜和简·E·基尔南，任期三年，至 2029 年年度会议结束。投票结果重申了现有董事会结构，并表明对公司当前战略方向的持续支持。</p>
</div><p>Stockholders also approved, on an advisory and non-binding basis, the executive compensation program for the company’s named executive officers, indicating broad investor backing of management’s pay practices. In addition, shareholders ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, reinforcing continuity in the company’s financial oversight and audit framework.</p>
<div class="lb-trans"><p>股东还以咨询和非约束性的方式批准了公司指定高管的薪酬计划，表明投资者对管理层薪酬做法的广泛支持。此外，股东确认了格兰特·桑顿会计师事务所作为截至 2026 年 12 月 31 日的财政年度独立注册公共会计师的任命，强化了公司财务监督和审计框架的连续性。</p>
</div><p>The most recent analyst rating on (TMCI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Treace Medical Concepts stock, see the TMCI Stock Forecast page.</p>
<div class="lb-trans"><p>对 (TMCI) 股票的最新分析师评级为持有，目标价为 2.00 美元。要查看 Treace Medical Concepts 股票的完整分析师预测列表，请参见 TMCI 股票预测页面。</p>
</div><p><strong>Spark’s Take on TMCI Stock</strong></p>
<div class="lb-trans"><p><strong>Spark 对 TMCI 股票的看法</strong></p>
</div><p>According to Spark, TipRanks’ AI Analyst, TMCI is a Neutral.</p>
<div class="lb-trans"><p>根据 Spark，TipRanks 的 AI 分析师，TMCI 的评级为中性。</p>
</div><p>The score is primarily held back by weak financial performance—ongoing losses and negative free cash flow—despite strong gross margins and some improvement in cash burn. Technicals are supportive short-term but appear overbought and still below the 200-day trend. Valuation offers limited support due to negative earnings, while the latest guidance indicates continued near-term revenue pressure alongside efforts to reduce cash usage.</p>
<div class="lb-trans"><p>该评分主要受到财务表现不佳的制约——持续亏损和负自由现金流——尽管毛利率强劲且现金消耗有所改善。技术面短期支持，但似乎被高估，仍低于 200 日均线。由于盈利为负，估值提供的支持有限，而最新指引表明，近期收入压力仍在持续，同时努力减少现金使用。</p>
</div><p>To see Spark’s full report on TMCI stock, click here.</p>
<div class="lb-trans"><p>要查看 Spark 对 TMCI 股票的完整报告，请点击这里。</p>
</div><p><strong>More about Treace Medical Concepts</strong></p>
<div class="lb-trans"><p><strong>关于 Treace Medical Concepts 的更多信息</strong></p>
</div><p>Treace Medical Concepts, Inc., a medical device company, develops and markets surgical solutions for foot and ankle conditions, with a particular focus on bunion correction procedures. The company targets orthopedic surgeons and podiatrists, positioning itself in the specialized orthopedic and podiatric surgery market within the broader medical technology industry.</p>
<div class="lb-trans"><p>Treace Medical Concepts, Inc. 是一家医疗设备公司，开发和营销针对足部和踝部疾病的外科解决方案，特别关注拇外翻矫正手术。该公司以骨科外科医生和足病医生为目标，在更广泛的医疗技术行业中定位于专业的骨科和足病外科市场。</p>
</div><p><strong>Average Trading Volume:</strong> 857,905</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 857,905</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> $178.4M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 1.784 亿美元</p>
</div>

Treace Medical 的股东支持董事会、薪酬方案和审计师